Service de Dermatologie, CHU Tokoin, Université de Lomé, Togo.
Int J Dermatol. 2012 Nov;51 Suppl 1:27-9, 30-2. doi: 10.1111/j.1365-4632.2012.05560.x.
This study aims at describing the clinical characteristics of patients with acne using skin bleaching (SB) products.
This is a prospective study conducted over 8 months in three dermatology departments and one private clinic. All patients examined for acne were included in the study.
The study included 119 patients examined for acne from March to October 2010. Among them 48 (40.7%) did SB. Hydroquinone was the first product used for SB (26 of 48), followed by topical corticosteroids (17 of 48). The elementary lesions were papules (99.2%), comedos (36.1%), pustules (63.9%), pigmentation (26.1%), scars (21%), and nodules (20.2%). The extent of acne on the face was observed in all patients (100%). The lesions were extensive among 43.7% of the patients. The extent of acne lesions was not statistically associated with SB. Other body areas concerned were the chest (20.2%), back, and shoulders (41.2%). The relative risk of having lesions on the back and/or shoulders when the patient practiced SB was 2.71 (CI: 1.08-6.84), which is significant.
The study suggests that the back and shoulders can be the main areas for acne lesions associated with the practice of SB. The influence of different types of product is unclear.
本研究旨在描述使用皮肤美白(SB)产品的痤疮患者的临床特征。
这是一项在三个皮肤科部门和一个私人诊所进行的为期 8 个月的前瞻性研究。所有检查痤疮的患者均纳入本研究。
本研究纳入了 2010 年 3 月至 10 月期间因痤疮就诊的 119 例患者。其中 48 例(40.7%)使用了 SB。氢醌是用于 SB 的第一种产品(48 例中的 26 例),其次是局部皮质类固醇(48 例中的 17 例)。原发性皮损为丘疹(99.2%)、粉刺(36.1%)、脓疱(63.9%)、色素沉着(26.1%)、瘢痕(21%)和结节(20.2%)。所有患者(100%)均观察到面部痤疮的严重程度。43.7%的患者皮损广泛。痤疮皮损的严重程度与 SB 之间无统计学关联。其他受累的身体部位包括胸部(20.2%)、背部和肩部(41.2%)。当患者使用 SB 时,背部和/或肩部出现皮损的相对风险为 2.71(CI:1.08-6.84),这具有统计学意义。
本研究表明背部和肩部可能是与 SB 相关的痤疮皮损的主要部位。不同类型产品的影响尚不清楚。